LY 2189102 / Eli Lilly - LARVOL DELTA

Safety, tolerability and efficacy of subcutaneous (SC) LY2189102, a neutralising IL-1b antibody, in patients (Pts) with type 2 diabetes (EASD 2011) - Presentation Time: Sep 14, 1:30 - 2:30 PM; P=NA, N=104; All 3 LY2189102 dose groups showed reduction in HbA1c at 12 wks compared to pbo; Numerical reduction in HbA1c remained evident at the end of 24 wks compared to pbo; Fasting glucose CFB was reduced compared to pbo at multiple timepoints and numerical estimates increased closer to baseline at 24 wks

Clinical data • Diabetes

Safety, tolerability and efficacy of subcutaneous (SC) LY2189102 (LY), a neutralizing IL-1β antibody, in patients (Pts) with type 2 diabetes (T2DM) (ADA 2011) - Presentation time: June 26, 2011: 12:00 PM - 2:00 PM; P2, N=106; All LY2189102 dose groups significantly reduced HbA1c at 12 wks compared to pbo with no obvious dose-response relationship; Numerical reduction remained evident at 24 wks compared to pbo; A significant (p<0.05), early reduction in C-reactive protein (CRP) occurred, with other inflammatory molecules also reduced

Diabetes

A Study of LY2189102 in Patients With Type 2 Diabetes -

Eli Lilly; P2, N=109;